Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914758029> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2914758029 endingPage "S462" @default.
- W2914758029 startingPage "S462" @default.
- W2914758029 abstract "Purpose: A combined analysis of two phase III, placebo-controlled studies (SPD476–301 and -302) has demonstrated mesalamine with MMX Multi Matrix System® (MMX) technology (LIALDA™, also known as MEZAVANT™ XL in the UK and Ireland, and as MEZAVANT™ elsewhere; hereafter referred to as MMX mesalamine) to be efficacious for the induction of remission of active, mild-to-moderate ulcerative colitis (UC), in patients with left-sided (distal to the splenic flexure) or extensive (involving the transverse colon) disease. In a subsequent 12-month extension study (SPD476–303), MMX mesalamine 2.4 g/day has demonstrated efficacy for maintenance of UC remission. Here we present a post-hoc analysis of 12-month remission rates with MMX mesalamine therapy in patients with a medical history of either left-sided or extensive UC. Methods: Patients were randomized to MMX mesalamine 2.4 g/day given once daily (QD) or 1.2 g given twice daily (BID) for 12 months. Remission was defined as a modified Ulcerative Colitis Disease Activity Index score ≤1, calculated as: scores of 0 for rectal bleeding and stool frequency, a combined Physician's Global Assessment and sigmoidoscopy score of ≤1, no mucosal friability, and a sigmoidoscopy score reduction of ≥1 from baseline. Results: In total, 451 patients were included in the efficacy population. Of the 450 with known extent of disease, 67.0% (233/348) and 64.7% (66/102) of patients with left-sided or extensive disease, respectively, were in remission at month 12. The results were similar with once- or twice-daily treatment in patients with left-sided (QD = 65.5%, BID = 68.4%, P= 0.570) or extensive disease (QD = 60.4%, BID = 68.5%, P= 0.393). Conclusion: MMX mesalamine 2.4 g/day is effective for the maintenance of remission of mild-to-moderate UC in both left-sided and extensive disease." @default.
- W2914758029 created "2019-02-21" @default.
- W2914758029 creator A5010408914 @default.
- W2914758029 creator A5025303269 @default.
- W2914758029 creator A5060703385 @default.
- W2914758029 creator A5081952210 @default.
- W2914758029 creator A5083435618 @default.
- W2914758029 creator A5089328133 @default.
- W2914758029 date "2007-09-01" @default.
- W2914758029 modified "2023-09-25" @default.
- W2914758029 title "MMX™ Mesalamine Is Effective for the Maintenance of Ulcerative Colitis Remission in Both Left-Sided and Extensive Disease" @default.
- W2914758029 doi "https://doi.org/10.14309/00000434-200709002-00936" @default.
- W2914758029 hasPublicationYear "2007" @default.
- W2914758029 type Work @default.
- W2914758029 sameAs 2914758029 @default.
- W2914758029 citedByCount "2" @default.
- W2914758029 crossrefType "journal-article" @default.
- W2914758029 hasAuthorship W2914758029A5010408914 @default.
- W2914758029 hasAuthorship W2914758029A5025303269 @default.
- W2914758029 hasAuthorship W2914758029A5060703385 @default.
- W2914758029 hasAuthorship W2914758029A5081952210 @default.
- W2914758029 hasAuthorship W2914758029A5083435618 @default.
- W2914758029 hasAuthorship W2914758029A5089328133 @default.
- W2914758029 hasConcept C111919701 @default.
- W2914758029 hasConcept C121608353 @default.
- W2914758029 hasConcept C126322002 @default.
- W2914758029 hasConcept C141071460 @default.
- W2914758029 hasConcept C142724271 @default.
- W2914758029 hasConcept C204787440 @default.
- W2914758029 hasConcept C27081682 @default.
- W2914758029 hasConcept C2778435480 @default.
- W2914758029 hasConcept C2779134260 @default.
- W2914758029 hasConcept C2779896975 @default.
- W2914758029 hasConcept C2780479503 @default.
- W2914758029 hasConcept C2908647359 @default.
- W2914758029 hasConcept C41008148 @default.
- W2914758029 hasConcept C526805850 @default.
- W2914758029 hasConcept C71924100 @default.
- W2914758029 hasConcept C85918911 @default.
- W2914758029 hasConcept C90924648 @default.
- W2914758029 hasConcept C99454951 @default.
- W2914758029 hasConceptScore W2914758029C111919701 @default.
- W2914758029 hasConceptScore W2914758029C121608353 @default.
- W2914758029 hasConceptScore W2914758029C126322002 @default.
- W2914758029 hasConceptScore W2914758029C141071460 @default.
- W2914758029 hasConceptScore W2914758029C142724271 @default.
- W2914758029 hasConceptScore W2914758029C204787440 @default.
- W2914758029 hasConceptScore W2914758029C27081682 @default.
- W2914758029 hasConceptScore W2914758029C2778435480 @default.
- W2914758029 hasConceptScore W2914758029C2779134260 @default.
- W2914758029 hasConceptScore W2914758029C2779896975 @default.
- W2914758029 hasConceptScore W2914758029C2780479503 @default.
- W2914758029 hasConceptScore W2914758029C2908647359 @default.
- W2914758029 hasConceptScore W2914758029C41008148 @default.
- W2914758029 hasConceptScore W2914758029C526805850 @default.
- W2914758029 hasConceptScore W2914758029C71924100 @default.
- W2914758029 hasConceptScore W2914758029C85918911 @default.
- W2914758029 hasConceptScore W2914758029C90924648 @default.
- W2914758029 hasConceptScore W2914758029C99454951 @default.
- W2914758029 hasLocation W29147580291 @default.
- W2914758029 hasOpenAccess W2914758029 @default.
- W2914758029 hasPrimaryLocation W29147580291 @default.
- W2914758029 hasRelatedWork W1974348321 @default.
- W2914758029 hasRelatedWork W1992700385 @default.
- W2914758029 hasRelatedWork W2020019737 @default.
- W2914758029 hasRelatedWork W2031161334 @default.
- W2914758029 hasRelatedWork W2040890002 @default.
- W2914758029 hasRelatedWork W2053902782 @default.
- W2914758029 hasRelatedWork W2078082429 @default.
- W2914758029 hasRelatedWork W2117513967 @default.
- W2914758029 hasRelatedWork W2165294540 @default.
- W2914758029 hasRelatedWork W2331464901 @default.
- W2914758029 hasVolume "102" @default.
- W2914758029 isParatext "false" @default.
- W2914758029 isRetracted "false" @default.
- W2914758029 magId "2914758029" @default.
- W2914758029 workType "article" @default.